Psoriasiform exfoliative erythroderma induced by golimumab

• DOI: 10.1111/ced.12402
• Publication Date: 2014-08-22T15:35:40Z
• Authors: S. Mateo; F. J. García-Mart...; D. Sánchez-Aguilar; J. Amarelo; J. Toribio
• Keywords: Golimumab; Exfoliative dermatitis; Erythroderma; Spondylitis

Golimumab is a fully human anti-tumour necrosis factor (TNF)-α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by with anti-TNF drugs well documented, but to our knowledge, development clinical features psoriasiform exfoliative erythroderma during golimumab has not been previously described.